vs
PROCORE TECHNOLOGIES, INC.（PCOR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
PROCORE TECHNOLOGIES, INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.7倍（$349.1M vs $207.3M），PROCORE TECHNOLOGIES, INC.净利率更高（-10.8% vs -62.0%，领先51.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 15.6%），PROCORE TECHNOLOGIES, INC.自由现金流更多（$109.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 13.8%）
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PCOR vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $349.1M | $207.3M |
| 净利润 | $-37.6M | $-128.6M |
| 毛利率 | 80.1% | — |
| 营业利润率 | -12.3% | -54.7% |
| 净利率 | -10.8% | -62.0% |
| 营收同比 | 15.6% | 25.9% |
| 净利润同比 | 39.6% | 3.5% |
| 每股收益（稀释后） | $-0.25 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $349.1M | $207.3M | ||
| Q3 25 | $338.9M | $159.9M | ||
| Q2 25 | $323.9M | $166.5M | ||
| Q1 25 | $310.6M | $139.3M | ||
| Q4 24 | $302.0M | $164.6M | ||
| Q3 24 | $295.9M | $139.5M | ||
| Q2 24 | $284.3M | $147.0M | ||
| Q1 24 | $269.4M | $108.8M |
| Q4 25 | $-37.6M | $-128.6M | ||
| Q3 25 | $-9.1M | $-180.4M | ||
| Q2 25 | $-21.1M | $-115.0M | ||
| Q1 25 | $-33.0M | $-151.1M | ||
| Q4 24 | $-62.3M | $-133.2M | ||
| Q3 24 | $-26.4M | $-133.5M | ||
| Q2 24 | $-6.3M | $-131.6M | ||
| Q1 24 | $-11.0M | $-170.7M |
| Q4 25 | 80.1% | — | ||
| Q3 25 | 79.7% | — | ||
| Q2 25 | 79.1% | — | ||
| Q1 25 | 79.1% | — | ||
| Q4 24 | 81.2% | — | ||
| Q3 24 | 81.4% | — | ||
| Q2 24 | 83.1% | — | ||
| Q1 24 | 83.0% | — |
| Q4 25 | -12.3% | -54.7% | ||
| Q3 25 | -4.4% | -106.9% | ||
| Q2 25 | -9.3% | -64.8% | ||
| Q1 25 | -11.7% | -102.6% | ||
| Q4 24 | -21.9% | -74.3% | ||
| Q3 24 | -12.3% | -94.6% | ||
| Q2 24 | -5.2% | -79.1% | ||
| Q1 24 | -7.0% | -151.9% |
| Q4 25 | -10.8% | -62.0% | ||
| Q3 25 | -2.7% | -112.8% | ||
| Q2 25 | -6.5% | -69.0% | ||
| Q1 25 | -10.6% | -108.5% | ||
| Q4 24 | -20.6% | -80.9% | ||
| Q3 24 | -8.9% | -95.7% | ||
| Q2 24 | -2.2% | -89.5% | ||
| Q1 24 | -4.1% | -156.8% |
| Q4 25 | $-0.25 | $-1.28 | ||
| Q3 25 | $-0.06 | $-1.81 | ||
| Q2 25 | $-0.14 | $-1.17 | ||
| Q1 25 | $-0.22 | $-1.57 | ||
| Q4 24 | $-0.42 | $-1.34 | ||
| Q3 24 | $-0.18 | $-1.40 | ||
| Q2 24 | $-0.04 | $-1.52 | ||
| Q1 24 | $-0.08 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $768.5M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $-80.0M |
| 总资产 | $2.2B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $768.5M | $421.0M | ||
| Q3 25 | $684.0M | $202.5M | ||
| Q2 25 | $620.9M | $176.3M | ||
| Q1 25 | $566.7M | $127.1M | ||
| Q4 24 | $775.4M | $174.0M | ||
| Q3 24 | $756.9M | $150.6M | ||
| Q2 24 | $735.4M | $480.7M | ||
| Q1 24 | $744.6M | $112.3M |
| Q4 25 | $1.3B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.2B | $151.3M | ||
| Q1 25 | $1.2B | $144.2M | ||
| Q4 24 | $1.3B | $255.0M | ||
| Q3 24 | $1.3B | $346.8M | ||
| Q2 24 | $1.3B | $432.4M | ||
| Q1 24 | $1.2B | $140.3M |
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.0B | $1.3B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $2.1B | $1.5B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $2.0B | $1.6B | ||
| Q1 24 | $1.9B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $109.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | 31.3% | -48.6% |
| 资本支出强度资本支出/营收 | 1.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $282.2M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $114.9M | $-99.8M | ||
| Q3 25 | $88.5M | $-91.4M | ||
| Q2 25 | $30.8M | $-108.3M | ||
| Q1 25 | $66.0M | $-166.5M | ||
| Q4 24 | $29.1M | $-79.3M | ||
| Q3 24 | $39.3M | $-67.0M | ||
| Q2 24 | $58.7M | $-77.0M | ||
| Q1 24 | $69.1M | $-190.7M |
| Q4 25 | $109.2M | $-100.8M | ||
| Q3 25 | $83.1M | $-92.7M | ||
| Q2 25 | $27.9M | $-110.7M | ||
| Q1 25 | $62.0M | $-167.8M | ||
| Q4 24 | $17.4M | $-79.5M | ||
| Q3 24 | $35.7M | $-68.6M | ||
| Q2 24 | $56.8M | $-79.0M | ||
| Q1 24 | $67.1M | $-193.9M |
| Q4 25 | 31.3% | -48.6% | ||
| Q3 25 | 24.5% | -58.0% | ||
| Q2 25 | 8.6% | -66.5% | ||
| Q1 25 | 20.0% | -120.5% | ||
| Q4 24 | 5.8% | -48.3% | ||
| Q3 24 | 12.1% | -49.2% | ||
| Q2 24 | 20.0% | -53.7% | ||
| Q1 24 | 24.9% | -178.2% |
| Q4 25 | 1.6% | 0.5% | ||
| Q3 25 | 1.6% | 0.8% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 3.9% | 0.1% | ||
| Q3 24 | 1.2% | 1.2% | ||
| Q2 24 | 0.7% | 1.4% | ||
| Q1 24 | 0.8% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
